[Treatment by lepirudin and acenocoumarol of heparin induced thrombocytopenia after valvular surgery: a word of caution].
The diagnosis and treatment of type II heparin-induced thrombocytopenia (HIT) after valvular surgery raise difficult issues due to the substitution of heparin by other anticoagulants. A 50-year-old man with hepatic cirrhosis and acute infective endocarditis underwent aortic valve replacement. On the 4th postoperative day platelet count decreased to 50 g/l. Platelet aggregation was demonstrated in vitro with unfractioned and low molecular weigh heparins and danaparoid sodium. As serum creatinine was 94 micromol/l, lepirudine (r-hirudin) was administered at recommended doses. However, six hours later hirudinaemia estimated by ecarin-clotting time was 3 mg/l and lepirudine dose had to be divided by 15 in order to reach therapeutic levels. Similarly, INR increased up to 6,7 on the 11th postoperative day after acenocoumarol 1 mg daily was administered. Despite the presence of oesophageal, gastric and duodenal lesions at risk of haemorrhage no bleeding was detected. The reasons for overdosage are discussed. The necessity of measurement or calculation of creatinine clearance before lepirudine prescription and frequent hirudinaemia during treatment is emphasized.
Lehot
J-J
JJ
Service d'anesthésie-réanimation, hôpital cardiovasculaire et pneumologique Louis-Pradel, BP Lyon-Montchat, 69394 Lyon cedex 03, France. bargol@aol.com <bargol@aol.com>
Gostoli
B
B
Ffrench
P
P
Berruyer
M
M
Hanss
M
M
D000074:Acenocoumarol / Q000627:therapeutic use*; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001021:Aortic Valve / Q000601:surgery*; D001777:Blood Coagulation; D006348:Cardiac Surgical Procedures; D004697:Endocarditis, Bacterial / Q000601:surgery*; D006493:Heparin / Q000009:adverse effects*; D006629:Hirudins / Q000009:adverse effects*; D006801:Humans; D019934:International Normalized Ratio; D008103:Liver Cirrhosis / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy
D000925:Anticoagulants; D006629:Hirudins; D011994:Recombinant Proteins; D006493:Heparin; D000074:Acenocoumarol; C083544:lepirudin